help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Wyk, J. J.
Right arrow Articles by Bruton, E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Wyk, J. J.
Right arrow Articles by Bruton, E. T.
Endocrinology Vol. 138, No. 10 4521-4523
Copyright © 1997 by The Endocrine Society


ARTICLES

Molecular Basis for Species and Ligand Specificity of a Monoclonal Antibody Raised Against Human IGF-I

Judson J. Van Wyk and Eyvonne T. Bruton

Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599

Address all correspondence and requests for reprints to: Judson J. Van Wyk, M.D., University of North Carolina, Department of Pediatrics, School of Medicine, 509 Clinical Science Building, CB# 7220, Chapel Hill, North Carolina 27599.

The anti-hIGF-I monoclonal antibody, {alpha}-sm1.2, was found to have substantial crossreactivity with human and rat IGF-II, but recognized rat IGF-I only when this ligand was present at very high concentration. (E50 for hIGF-I ~3.5 ng/tube vs. ~12,000 ng/tube for rat IGF-I). In the context of previous studies to define the epitope(s) of {alpha}-sm1.2, these findings point to the critical importance of aspartic acid at residue 20 in the B domain in determining the species and ligand specificity of this antibody. Previous studies using this antibody in rodent tissues may require reinterpretation in the light of these findings.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
B. P Hauffa, N. Lehmann, M. Bettendorf, O. Mehls, H.-G. Dorr, N. Stahnke, H. Steinkamp, E. Said, M. B Ranke, and participating members of the German KIGS Board/Med
Central laboratory reassessment of IGF-I, IGF-binding protein-3, and GH serum concentrations measured at local treatment centers in growth-impaired children: implications for the agreement between outpatient screening and the results of somatotropic axis functional testing
Eur. J. Endocrinol., November 1, 2007; 157(5): 597 - 603.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. G. Simmons, J. B. Pucilowska, and P. K. Lund
Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors
Am J Physiol Gastrointest Liver Physiol, April 1, 1999; 276(4): G817 - G827.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society